Kornimate/medical-research-clean huggingface dataset:
ifact: incidental findings in advanced cancer therapy

Conditions: Breast Cancer; Colorectal Cancer; Bladder Cancer; Lung Cancer

Summary: the proposed study, ifact - incidental findings in advanced cancer therapy, will address this research gap by examining msk patients' attitudes, preferences, and information needs regarding incidental findings arising from tumor genomic profiling.

part 1, the investigators will recruit 40 participants from those already enrolled in existing msk irb protocol #12-245 (pi: david hyman, md) including male and female patients who have been diagnosed with late-stage breast, colorectal, bladder, and lung cancer (some of the most common cancers in this study population). part 2, the investigators will recruit 20 participants from those who have actually received incidental germline findings from msk irb protocol #12-245 consent part c in order to cognitively test novel survey items about their knowledge and perceived utility of their incidental findings (note that the content of these items will be derived from the data collected in part 1)

Eligibility criteria:
inclusion criteria: part 1: * patient enrolled on msk protocol #12-245 * living patient age 18 or older * patient diagnosed with breast cancer, colorectal cancer, bladder cancer, or lung cancer * patient residing in new york metro-area part 2: * living patient age 18 or older * consented to part c of irb#12-245 and has received results regardless if thereir was a pathogenic variant * patient diagnosed with cancer type approved for irb#12-245 part c (which are currently breast cancer, gynecological cancer, prostate cancer, and gu non-prostate cancer)breast cancer, colorectal cancer, bladder cancer, or lung cancer * patient residing in new york metro-area exclusion criteria for part 1 and 2: * non-english speakers because we do not have the resources to conduct and translate the interviews into other languages. * patient unwilling or unable to provide informed consent.
phase ii study of dcvac/pca added to hormone therapy for men with metastatic prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to determine whether dcvac/pca added onto hormone therapy can improve psa progression times for patients with metastatic prostate cancer.

use of vaccine to improve prostate specific antigen (psa) levels.

Eligibility criteria:
inclusion criteria: * male 18 years and older * histologically confirmed prostate adenocarcinoma * presence of bone or soft tissue metastasis (by ct or pet or mri and/or scintigraphy) * androgen deprivation therapy using luteinizing-hormone-releasing hormone ( lhrh) analogues commenced at least one month and at most three months prior randomization or orchiectomy performed at least one month and at most three months prior randomization * serum testosterone level at screening (≤ 1.7 nmol/l, resp. ≤ 50 ng/dl) * eastern cooperative oncology group (ecog) 0-2 exclusion criteria: * confirmed brain and/or leptomeningeal metastases * prior or ongoing chemotherapy for prostate cancer * peripheral neuropathy of common toxicity criteria (ctc) grade 2 or greater * other uncontrolled intercurrent illness * treatment with immunotherapy against prostate cancer * clinically significant cardiovascular disease * active autoimmune disease requiring treatment

Keywords: immunotherapy prostate cancer biological vaccine androgen deprivation therapy
investigation of hyperhidrosis treatment using the nd: yag 1440nm wavelength laser

Conditions: HYPERHIDROSIS

Summary: the purpose of this study is to evaluate the safety and efficacy of the nd:yag 1440 nm wavelength laser for the treatment of primary hyperhidrosis of the axilla.


Eligibility criteria:
inclusion criteria: * a healthy non-smoking male or female between 18-56 years of age * understand/accept obligation not to receive any other procedures in anatomical areas exhibiting axillary hyperhidrosis through 3 months prior to treatment * understand and accept the obligation and is logistically able to present for all scheduled follow-up visits * clinically diagnosed for primary hyperhidrosis of the axilla. * a self assessed hyperhidrosis disease severity scale (hdss) score of three (3) or four (4) exclusion criteria: * clinical diagnosis of secondary hyperhidrosis * uncontrolled systemic disease * concurrent use of any hyperhidrosis treatments other than over the counter antiperspirants or deodorants * receipt of botox or dysport within the past six months * patients who refuse to stop using over the counter antiperspirants 24 hours prior to the day of surgery and each of the follow-up visits at 3 months and 6 months that minors starch iodine tests may be performed. * patients using or having used within 7 days of baseline visit: cholinomimetic agents, anticholinergic agents, prescription antiperspirants, any herbal medicine treatments or any other treatments for hyperhidrosis except over the counter antiperspirant or planning to use such agents during the course of the study. * any previous liposuction/liposculpture or any type of surgery for hyperhidrosis; or any other types of treatments for hyperhidrosis in the area to be treated in the past 6 months or planning to have any treatments for hyperhidrosis or surgery within the treatment area during the course of the study. * allergies to medication or local anesthesia required for the procedure * a history of thrombophlebitis * a history of acute infections * a history of heart failure * received or is anticipated to receive antiplatelets, anticoagulants, thrombolytics, vitamin e or anti inflammatories within 2 weeks pre treatment * an intolerance to anesthesia * any medical condition, that, in the investigator's opinion would interfere with the patient's participation in the study * taking medications that are photosensitive * a history of keloid formation * is pregnant or has been pregnant in the last 3 months, currently breast feeding or planning a pregnancy during the course of the study * study subjects that can not maintain their pre-study exercise and diet routine over the course of the study
risk factors for implant bone loss in patients with diabetes mellitus

Conditions: Diabetes

Summary: dental implants are regarded as a standard of care in restoring missing teeth. although there is a high prevalence of diabetics who receive dental implants, the relationship between dental implants and diabetes has not clearly been investigated. a total of 32 subjects (14 patients with type ii diabetes and 18 non-diabetes subjects) who have dental implants were recruited. the purposes of this research study were: (1) to evaluate diabetes patients to determine risk factors for bone loss at dental implants and teeth; and (2) to evaluate bone-resorptive biomarkers (proteins related to bone loss) present in saliva and blood serum, comparing the two groups.

objective: regulators of peri-implant bone loss in patients with diabetes appear to involve multiple risk factors that have not been clearly elucidated. this study was conducted to explore putative local etiologic factors on implant bone loss in relation to type 2 diabetes mellitus, including clinical, microbial, salivary biomarker, and psychosocial factors. materials and methods: thirty-two subjects (divided into type 2 diabetes mellitus and non-diabetic controls), having at least one functional implant and six teeth, were enrolled in a 1-year longitudinal investigation. analyses of clinical measurements and standardized intra-oral radiographs, saliva and serum biomarkers (via protein arrays for 20 selected markers), and plaque biofilm (via qpcr for eight periodontal pathogens) were performed at baseline and 1 year. in addition, the subjects were asked to respond to questionnaires to assess behavioral and psychosocial variables.

Eligibility criteria:
inclusion criteria: * be at least 40 years old * have at least one dental implant that has been in function for at least 6 months * have at least 6 natural teeth * have good general oral health * not be pregnant or breastfeeding or planning to become pregnant within the next year * if you are a pre-menopausal woman you or your male partner must be surgically sterile or you must be using reliable birth control (i.e., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch) now and throughout the study or abstain from sex throughout the study exclusion criteria: * not have an active oral infection, including periodontitis and rampant caries * not have a history of chronic systemic illness or infection, history of oral cancer, life expectancy of less than 5 years * not have had cancer treatment in the last 12 months

Keywords: healthy
binimetinib plus encorafenib real life investigation of next generation melanoma treatment

Conditions: Melanoma Stage IV; Melanoma Stage III

Summary: bering-melanoma - designed as a prospective, longitudinal, non-interventional study - investigates real-world effectiveness, quality of life, safety and tolerability of encorafenib plus binimetinib in unresectable advanced or metastatic braf(rapidly accelerated fibrosarcoma isoform b)-v600-mutant malignant melanoma after commercial availability of these two products in germany, austria and switzerland. the study focusses on the documentation of the first and second line setting (i.e. after one line of prior checkpoint inhibition) by documenting patients treated according to the smpc (summary of product characteristics).


Eligibility criteria:
inclusion criteria: * written informed consent of the patient with regard to the pseudonymized documentation as well as the transfer and processing of his/her data within the study and the adoreg \[cancer registry of german working group of dermato-oncology\] registry (data transfer to adoreg registry only for patients from german sites); * legally capable male or female patient ≥ 18 years of age (no upper limit); * decision was taken to treat the patient with encorafenib plus binimetinib in accordance with the current smpc \[summary of product characteristics\] and by prescription; this decision was taken prior to and independent from the inclusion into the study; * treatment with encorafenib plus binimetinib has been started ≤ 6 months prior to providing written informed consent for this study or is planned to be started in the near future; * unresectable advanced or metastatic malignant melanoma with braf \[rapidly accelerated fibrosarcoma isoform b\] v600 mutation; * treatment-naive or after one prior line of checkpoint inhibitor treatment (anti-ctla4 \[cytotoxic t-lymphocyte antigen-4\] and/or anti-pd(l)1 \[programmed cell death protein 1\]) in the unresectable advanced or metastatic setting. exclusion criteria: * previous treatment with a braf- and/or mek \[mitogen-activated protein/extracellular-signal regulated kinase\]- inhibitor except for: -- prior adjuvant treatment with braf+mek-inhibitor combination therapy that ended \> 6 months prior start of encorafenib/binimetinib treatment; * more than one prior line of checkpoint inhibitor treatment in the unresectable advanced or metastatic setting; * any previous chemotherapeutic treatment of the melanoma disease; * presence of any contraindication with regard to the encorafenib-binimetinib-treatment as specified in the corresponding smpcs; * current or upcoming participation in an interventional clinical trial; * current or upcoming systemic treatment of any other tumor than melanoma; * prisoners or persons who are compulsorily detained (involuntarily incarcerated).

Keywords: bering encorafenib binimetinib
melatonin's effect on nighttime blood pressure and sleep in osa patients (mebp-osa)

Conditions: Obstructive Sleep Apnea of Adult

Summary: the goal of this clinical trial is to learn if melatonin works to treat comorbid insomnia in adults with osa and nocturnal non-dipping blood pressure pattern. the main question it aims to answer is: does melatonin maintain sleep during night and recover the dipping blood pressure pattern?

the goal of this clinical trial is to learn if melatonin works to treat comorbid insomnia in adults with osa and nocturnal non-dipping blood pressure pattern. the main question it aims to answer is: does melatonin maintain sleep during night and recover the dipping blood pressure pattern? participants will: * take melatonin or the habitual treatment every day for one month * visit the clinic 11 times for one month * keep a diary of their symptom and activities and use twice a 24 h ambulatory blood pressure monitoring (abpm), attend two overnight polysomnography studies, and use an actigraph every day for 2 weeks. researchers will compare melatonin to the habitual treatment to see if melatonin works to treat insomnia and recover the dipping blood pressure pattern. the medical problems that participants would have when taking melatonin are: * changes in blood pressure and cholesterol * increased risk of contracting immune system disorders * possible increased risk of liver damage.

Eligibility criteria:
inclusion criteria: * polisomnographic diagnosis of obstructive sleep apnea * non-dipping blood pressure on ambulatory blood pressure monitoring (abpm): exclusion criteria: * use of sleep or psychiatric medication * use of positive airway pressure (cpap or bipap) * neurologic or psychiatric disorder

Keywords: circadian blood pressure rhythm obstructive sleep apnea melatonin
mr-evaluation of renal function in septic patients

Conditions: Sepsis, Severe; Acute Kidney Injury; COVID-19

Summary: a study of renal blood flow and renal oxygenation measured by magnetic resonance after a standardized fluid challenge in critically ill, resuscitated, patients with sepsis due to covid-19 or other agents.

critically ill, septic patients with or without acute kidney injury (aki) above 18 years of age who have been circulatory and respiratory stabilized will be screened for inclusion. after the patients have been adequately treated with antimicrobial agents, source control and circulatory and respiratory stabilized, the patient will be moved to the magnetic resonance imaging (mri)-suite and placed in the mri-camera. we plan to, at the same time, study renal blood flow (rbf) and oxygenation with 4 different mri techniques; arterial spin labeling (asl), blood oxygen level dependent (bold)-technique, t(2) -relaxation-under-spin-tagging (trust) and phase contrast at two conditions; 1. at baseline after stabilization 2. after intravenous infusion of 7,5 ml/kg ml ringer's acetate the following data will be registered: 1. age, gender, length and weight, 2. concomitant diseases and treatment, 3. present disease and treatment, 4. source of admission - emergency department or ordinary ward, 5. daily laboratory reports, 6. results from other investigations, e.g. x-rays, cultures etc., 7. recordings from the intensive care unit (icu) monitors 8. continuous renal replacement therapy (crrt) - duration type, flow rate, replacement fluid, etc. 9. dead or alive at discharge and 90 days mortality, 10. renal function at discharge, 11. treatment restrictions, 12. if the patient has died, the results from a possible postmortem examination. as well as all data obtained during the mri-examination.

Eligibility criteria:
inclusion criteria: * patients with clinical diagnosis sepsis (infection and organ dysfuncion) treated in intensive care. * manifest acute kidney injury (aki) or risk of aki. * 18 years of age or older exclusion criteria: * pregnancy * chronic kidney failure * renal replacement therapy * instability in vital parameters to a degree where mri is not feasible * contraindications for mri (implants, coils, pacemakers, etc)

Keywords: magnetic resonance imaging fluid therapy renal circulation renal oxygenation
follow-up study of population vaccinated with covid-19 vaccine

Conditions: Healthy

Summary: a multi-centered clinical follow-up study to investigate the long-term dynamic of covid-19 antibody level after vaccination.

from december 2019, coronavirus disease 2019 (covid-19), caused by a β-coronavirus known as severe acute respiratory syndrome coronavirus 2 (sars-cov-2), has spread across the globe. as of july 6, 2021, more than 180 million confirmed cases and around 4 million deaths have been reported globally. till now, many treatment methods has gradually formed a consensus. at the same time, several domestic vaccines have been offered to the public for free inoculation in our country. however, due to the urgent form of the epidemic, the short vaccine development cycle and heavy tasks, there is no clear conclusion on the long-term changes in antibody levels after vaccination.therefore, we plan to carry out a multi-center prospective observational trial to better understand the dynamic changes of the antibody levels in patients after vaccination.

Eligibility criteria:
inclusion criteria: * adult (18 years old or elder) who prepare or have been vaccinated against covid-19, and has not participated in similar clinical studies. exclusion criteria: * people who are allergic to any active ingredient of the vaccine, any inactive ingredient which was used in the production process, or those who have been allergic to the same kind of vaccine before. * people who have had severe allergic reaction to vaccine before (such as acute allergic reaction, vascular neuroedema, dyspnea, etc.) * people with uncontrolled epilepsy and other serious neurological diseases (such as transverse myelitis, guillain-barre syndrome, demyelinating diseases, etc.) * people who are feverish, or suffering from acute diseases, or suffering from acute episodes of chronic diseases, or with serious chronic diseases without control. * pregnant woman * juvenile

Keywords: covid-19 vaccination anti-body
physical exercise and dairy probiotics in childhood cancer survivors

Conditions: Acute Lymphoblastic Leukemia, Pediatric

Summary: the goal of this clinical trial is to to compare the structure of the intestinal microbiome between children shortly after treatment for acute lymphoblastic leukemia (1-3 years after cancer treatment) and healthy controls. and then to provoke a positive shift of bacterial diversity by physical activity and probiotics in cured pediatric oncology patients with persistent gut microbiome disruptions. the main question\[s\] it aims to answer are: * are differences in bacterial richness between healthy controls and pediatric oncology patients ≥12 months after cancer treatment apparent? * has the combination of physical exercise and probiotics had a positive influence on the structure of the gut microbiome in childhood cancer survivors in remission? two times per week of physical activity and daily dairy consumption with probiotics will be required of participants for eight weeks.


Eligibility criteria:
inclusion criteria: - children previously diagnosed and treated for acute lymphoblastic leukemia in remission between 1 and 3 years exclusion criteria: * acute respiratory infection during intervention * more than 20% skipped exercise training sessions

Keywords: physical exercise, gut microbiome, exercise training, veillonella
an evaluation of pentoxifylline in hiv-positive persons with symptomatic hiv infection and a karnofsky score > 40 percent and < 100 percent

Conditions: HIV Infections

Summary: primary: to determine whether pentoxifylline changes the self-reported measures of quality of life status, using measures of scores from double-blinded drug withdrawal and drug restart periods. secondary: to measure the changes in monthly cd4 counts, fasting serum triglyceride levels, and weight; to assess the safety of pentoxifylline in hiv-infected persons.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * stable antiretroviral therapy. * maintenance medication for opportunistic infection. patients must have: hiv positivity. note: * patients on an antiretroviral must have received it for at least 2 months and have no currently perceived need to change or add to the regimen for the next 3 months. prior medication: allowed: * antiviral therapy (provided patient has been on such therapy for at least 2 months at study entry and dose is stable). exclusion criteria co-existing condition: patients with the following symptoms and conditions are excluded: * evidence of active opportunistic infection or malignancy requiring high-dose systemic chemotherapy (only patients who are 30 days from a diagnosis of an opportunistic infection and on appropriate maintenance medication are allowed). * known significant intolerance or hypersensitivity to theophylline, theobromine (chocolate), or caffeine, for reasons other than dyspepsia. * inability to swallow tablets (gastric feeding tubes are allowed). * active bleeding disorder or major bleeding source, including peptic ulcer or gastritis. * any symptoms suggestive of concurrent illness that are not attributable to overall impairment by hiv or are not diagnosable based on the available evidence. * not willing to comply with visit schedule and study procedures. concurrent medication: excluded: * concurrent use of the anticoagulant warfarin (coumadin) and heparin. prior medication: excluded: * treatment with biologic response modifiers (e.g., interferon, interleukin) within 14 days prior to study entry. prior treatment: excluded: * major surgery within 30 days of study entry.

Keywords: pentoxifylline acquired immunodeficiency syndrome aids-related complex
effect of vitamin e supplementation in methylation and micrornas profile

Conditions: Obesity

Summary: it is a study of clinical and interventional character, in which individuals who participate in the intervention will be selected for convenience of the project database entitled "second cycle diagnosis and intervention food situation, nutrition and noncommunicable disease more prevalent population of the city of joão pessoa / pb ". they will be invited to participate in the intervention female subjects, overweight or obese, aged 20 and 59 years. the selected individuals will be distributed randomly into four groups: receive daily supplementation of 01 capsules containing 400 mg of vitamin e synthetic source (group 1); receive daily supplementation of 01 capsules containing 400 mg of natural source vitamin e (group 2); receive daily supplementation of 01 placebo capsule (control group); and non-intervention group. individuals of intervention groups will receive dietary plan respecting individual needs, in order to control weight during the 08 weeks period. the subjects of the group without intervention, did not follow a diet plan, nor did they take vitamin e or placebo capsules, and were asked to continue their current eating habits over the 8-week period this project aims to evaluate whether vitamin e supplementation may modify the methylation and micrornas profile.


Eligibility criteria:
inclusion criteria: * female subjects; * persons aged between 20 and 59 years; * overweight or obese; exclusion criteria: * individuals consumed alcohol and / or chronic smokers; * individuals who do not have preserved cognitive status; * individuals users of multivitamins and mineral supplements, appetite suppressants and steroids; * pregnant women.